.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,987,262

« Back to Dashboard

Details for Patent: 8,987,262

Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Benoit (Bordeaux, FR)
Assignee: Universite de Bordeaux (Bordeaux, FR) Centre Hospitalier Universitaire de Bordeaux (Talence, FR)
Filing Date:Nov 16, 2012
Application Number:13/678,802
Claims:1. A method for treating a patient having a capillary or infantile hemangioma, comprising administering to the patient a pharmaceutically acceptable and efficient dose of a beta blocker.

2. The method of claim 1, wherein the beta blocker is selected from the group consisting of non-selective beta blockers, beta-1-selective beta blockers, mixtures of alpha-1/beta-adrenergic antagonists, beta-2-selective beta blockers, and mixtures of two or more beta-blockers.

3. The method of claim 1, wherein the beta blocker is a non-selective beta blocker.

4. The method of claim 3, wherein the non-selective beta blocker is selected from the group comprising alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propafenone, propranolol, sotalol, timolol, pharmaceutically acceptable salts thereof and mixtures thereof.

5. The method of claim 1, wherein the beta blocker is a beta-1 selective beta blocker.

6. The method of claim 5, wherein the beta-1 selective beta blocker is selected for example from the group comprising acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, esmolol, metoprolol, and nebivolol.

7. The method of claim 1, wherein the beta blocker has an intrinsic sympathomimetic activity.

8. The method of claim 7, wherein the beta blocker is selected from the group comprising acebutolol, betaxolol, carteolol, carvedilol, labetalol, oxprenolol, penbutolol, pindolol, and propranolol.

9. The method of claim 1, wherein the beta-blocker is acebutolol.

10. The method of claim 1, wherein the beta-blocker is timolol.

11. The method of claim 1, wherein the hemangioma is an infantile hemangioma.

12. The method of claim 1, wherein the medicament is for oral administration, and is selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms.

13. The method of claim 12, wherein the medicament for oral administration is a liquid formulation selected from the group consisting of solutions, syrups, suspensions, emulsions and oral drops.

14. The method of claim 13, wherein the medicament is for topical administration and is selected from the group consisting of ointments, creams, gels, lotions, patches, and foams.

15. The method of claim 1, wherein the medicament is for nasal, buccal, sublingual, or rectal administration.

16. The method of claim 1, wherein the medicament is administered at a daily dose of less than or equal to 20 mg/kg of body weight of the patient.

17. The method of claim 16, wherein the dose is less than or equal to 10 mg/kg of body weight of the patient.

18. A method for treating a patient having an infantile hemangioma, comprising administering to the patient a pharmaceutically acceptable and efficient dose of a beta blocker at a dose of less than or equal to 10 mg/kg of body weight.

19. The method of claim 18, wherein the beta blocker is selected from the group consisting of alprenolol, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, labetolol, nadolol, penbutolol, propranolol, timolol, metoprolol, and combinations thereof.

20. The method of claim 18, comprising administering to the patient a pharmaceutically acceptable and efficient dose of timolol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc